CuroVax Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 303

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 20

CuroVax General Information

Description

Manufacturer of human vaccine products and immunization technologies aims to advance global public health through innovative vaccine development. The company's offerings feature end-to-end capabilities in independent R&D, large-scale mammalian cell culture, antigen purification, mRNA vaccine platforms, and full-cycle GMP manufacturing across 41000 square meters of certified production space, helping healthcare providers and governments deliver safe and effective vaccines, enabling broad immunization coverage and improved global disease prevention.

Contact Information

Website
www.curovax.net
Formerly Known As
Jiangsu Simcere Biopharmaceutical Co., Ltd., Jiangsu Innovent Biological Medicine Research Co., Ltd., Jiangsu Xiansheng Weike Biopharmaceutical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 88 Kunlun Road
  • Xinbei District
  • Changzhou, Jiangsu 213022
  • China
+86 139
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • Number 88 Kunlun Road
  • Xinbei District
  • Changzhou, Jiangsu 213022
  • China
+86 139

CuroVax Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CuroVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 07-Jul-2025 Completed Generating Revenue
10. Later Stage VC (Series C1) 06-Jul-2025 Completed Generating Revenue
9. Later Stage VC 07-Apr-2024 Completed Generating Revenue
8. Secondary Transaction - Private 07-Apr-2024 Completed Generating Revenue
7. Later Stage VC 01-Jan-2024 Completed Generating Revenue
6. Later Stage VC (Series C) 24-May-2023 Completed Generating Revenue
5. Later Stage VC (Series B1) 06-Jul-2022 Completed Generating Revenue
4. Later Stage VC (Series B) 19-Aug-2021 Completed Generating Revenue
3. Later Stage VC (Series A) 24-Nov-2020 Completed Generating Revenue
2. Later Stage VC 14-Apr-2020 Completed Generating Revenue
To view CuroVax’s complete valuation and funding history, request access »

CuroVax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CuroVax Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioTrack Capital Venture Capital Minority
Green Pine Capital Partners Venture Capital Minority
Hangzhou Tigermed Consulting Company Corporation Minority
Hankang Capital Growth/Expansion Minority
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

CuroVax Acquisitions (1)

CuroVax’s most recent deal was a Merger/Acquisition with Delonix Bioworks. The deal was made on 31-Dec-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Delonix Bioworks 31-Dec-2023 Merger/Acquisition Other Pharmaceuticals and Biotechnology
To view CuroVax’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

CuroVax Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Delonix Bioworks Shanghai, China 2021

CuroVax FAQs

  • When was CuroVax founded?

    CuroVax was founded in 2011.

  • Where is CuroVax headquartered?

    CuroVax is headquartered in Changzhou, China.

  • What is the size of CuroVax?

    CuroVax has 303 total employees.

  • What industry is CuroVax in?

    CuroVax’s primary industry is Biotechnology.

  • Is CuroVax a private or public company?

    CuroVax is a Private company.

  • What is CuroVax’s current revenue?

    The current revenue for CuroVax is .

  • How much funding has CuroVax raised over time?

    CuroVax has raised $73.5M.

  • Who are CuroVax’s investors?

    BioTrack Capital, Green Pine Capital Partners, Hangzhou Tigermed Consulting Company, Hankang Capital, and Boehringer Ingelheim Venture Fund are 5 of 20 investors who have invested in CuroVax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process